Therapeutic use of blocking antibodies to either PD-L1 or PD-1 has produced unparalleled, durable clinical responses in a wide variety of solid and hematologic cancers6, 7, 8, 9, 10, presumably by relieving suppression of primed T cells within the tumour microenvironment. Here, CD274 is linked to neoplasm.